Compare INLF & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLF | PMVP |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | China | United States |
| Employees | 156 | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 76.8M |
| IPO Year | N/A | 2020 |
| Metric | INLF | PMVP |
|---|---|---|
| Price | $3.19 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 49.3K | ★ 436.3K |
| Earning Date | 03-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.83 |
| 52 Week High | $5.20 | $1.88 |
| Indicator | INLF | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 54.46 |
| Support Level | $0.40 | $1.37 |
| Resistance Level | $5.20 | $1.50 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 0.00 | 70.37 |
INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.